Verrica Pharmaceuticals announced positive topline results from its Phase III CAMP-1 and CAMP-2 pivotal trials with VP 102 (cantharidin 0.7%)...
Verrica Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for VP 102 (cantharidin 0.7% Topical Solution), a...
Verrica Pharmaceuticals Inc. presented data from the company’s pivotal Phase III CAMP-1 and CAMP-2 trials of lead product candidate, VP...
Verrica Pharmaceuticals Inc. announced that the Company received a letter from the FDA as part of the FDA’s ongoing review of the Company’s New Drug Application (NDA) for VP 102 (cantharidin 0.7% topical solution), Verrica’s lead product candidate for the treatment of molluscum contagiosum.
Baxter International Inc. announced that the company has submitted a biologics license application (BLA) to the FDA for the approval...
Verrica Pharmaceuticals Inc. announced that the FDA has issued a Complete Response Letter regarding its New Drug Application (NDA) for VP 102 for the treatment of molluscum contagiosum (molluscum).
Verrica Pharmaceuticals Inc. has announced that the FDA has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP 102 for the treatment of molluscum contagiosum (molluscum).
The acute hepatic porphyrias (AHP) are a group of four inherited diseases of heme biosynthesis. They present with similar severe, episodic, acute neurovisceral symptoms due to abnormally elevated levels of porphyrin precursors delta-aminolevulinic acid (ALA).
Purpose: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC).
Background: Porphyrias are a group of rare diseases leading to dysregulation in heme biosynthesis and the accumulation of heme precursors, including porphyrinogens, which in their oxidized states [porphyrins] are reddish or purple.